INOVIO Pharmaceuticals
NEWS ALERT

FDA Accepts for Review INOVIO’s BLA for INO-3107 for the Treatment of Adults with Recurrent Respiratory Papillomatosis (RRP)

Press Releases

Immune Response Data for INO-3107 to be Presented as a Poster at American Association for Cancer Research Immuno-Oncology (AACR-IO) Conference

Posted on February 10, 2025

INOVIO to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Posted on January 29, 2025

INOVIO Highlights Anticipated 2025 Milestones and 2024 Key Accomplishments

Posted on January 9, 2025

INOVIO Announces Pricing of $30 Million Public Offering

Posted on December 13, 2024

INOVIO Announces Proposed Public Offering

Posted on December 12, 2024

New Retrospective Data Shows Half of RRP Patients Treated with INO-3107 Achieved a Complete Response When Evaluated 2 and 3 Years Following Initial Phase 1/2 Trial

Posted on December 3, 2024

INOVIO Reports Third Quarter 2024 Financial Results and Recent Business Highlights

Posted on November 14, 2024

Immunology Data Shows INOVIO’s INO-3107 Induced Expansion of New Clonal T Cells That Infiltrate Airway Tissue and Correspond With Reduction of Surgeries for RRP Patients Observed in Phase 1/2 Trial

Posted on November 13, 2024

INOVIO to Report Third Quarter 2024 Financial Results on November 14, 2024

Posted on November 6, 2024

INOVIO Announces New Data at Scientific Conferences for Lead Candidate, INO-3107, as a Potential Treatment for RRP

Posted on October 21, 2024

SUBSCRIBE FOR UPDATES FROM INOVIO
Register to receive email alerts for INOVIO press releases

© Copyright 2026 INOVIO Pharmaceuticals. All rights reserved.